These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15081017

  • 1. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.
    Byth KF, Culshaw JD, Green S, Oakes SE, Thomas AP.
    Bioorg Med Chem Lett; 2004 May 03; 14(9):2245-8. PubMed ID: 15081017
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
    Jaramillo C, de Diego JE, Hamdouchi C, Collins E, Keyser H, Sánchez-Martínez C, del Prado M, Norman B, Brooks HB, Watkins SA, Spencer CD, Dempsey JA, Anderson BD, Campbell RM, Leggett T, Patel B, Schultz RM, Espinosa J, Vieth M, Zhang F, Timm DE.
    Bioorg Med Chem Lett; 2004 Dec 20; 14(24):6095-9. PubMed ID: 15546737
    [Abstract] [Full Text] [Related]

  • 4. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
    Hamdouchi C, Zhong B, Mendoza J, Collins E, Jaramillo C, De Diego JE, Robertson D, Spencer CD, Anderson BD, Watkins SA, Zhang F, Brooks HB.
    Bioorg Med Chem Lett; 2005 Apr 01; 15(7):1943-7. PubMed ID: 15780638
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
    Finlay MR, Acton DG, Andrews DM, Barker AJ, Dennis M, Fisher E, Graham MA, Green CP, Heaton DW, Karoutchi G, Loddick SA, Morgentin R, Roberts A, Tucker JA, Weir HM.
    Bioorg Med Chem Lett; 2008 Aug 01; 18(15):4442-6. PubMed ID: 18617397
    [Abstract] [Full Text] [Related]

  • 7. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
    Bamford MJ, Bailey N, Davies S, Dean DK, Francis L, Panchal TA, Parr CA, Sehmi S, Steadman JG, Takle AK, Townsend JT, Wilson DM.
    Bioorg Med Chem Lett; 2005 Jul 15; 15(14):3407-11. PubMed ID: 15955699
    [Abstract] [Full Text] [Related]

  • 8. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
    Buckley GM, Ceska TA, Fraser JL, Gowers L, Groom CR, Higueruelo AP, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3291-5. PubMed ID: 18482836
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
    Kim O, Jeong Y, Lee H, Hong SS, Hong S.
    J Med Chem; 2011 Apr 14; 54(7):2455-66. PubMed ID: 21388141
    [Abstract] [Full Text] [Related]

  • 15. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
    Lin R, Lu Y, Wetter SK, Connolly PJ, Turchi IJ, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Adams M, Pandey N, Moreno-Mazza S, Middleton SA, Jolliffe LK.
    Bioorg Med Chem Lett; 2005 May 02; 15(9):2221-4. PubMed ID: 15837297
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
    Lee J, Choi H, Kim KH, Jeong S, Park JW, Baek CS, Lee SH.
    Bioorg Med Chem Lett; 2008 Apr 01; 18(7):2292-5. PubMed ID: 18353638
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S, Wood G, Meades C, Griffiths G, Midgley C, McNae I, McInnes C, Anderson S, Jackson W, Mezna M, Yuill R, Walkinshaw M, Fischer PM.
    Bioorg Med Chem Lett; 2004 Aug 16; 14(16):4237-40. PubMed ID: 15261277
    [Abstract] [Full Text] [Related]

  • 18. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
    Anderson M, Andrews DM, Barker AJ, Brassington CA, Breed J, Byth KF, Culshaw JD, Finlay MR, Fisher E, McMiken HH, Green CP, Heaton DW, Nash IA, Newcombe NJ, Oakes SE, Pauptit RA, Roberts A, Stanway JJ, Thomas AP, Tucker JA, Walker M, Weir HM.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5487-92. PubMed ID: 18815031
    [Abstract] [Full Text] [Related]

  • 19. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.
    J Med Chem; 2006 Nov 02; 49(22):6500-9. PubMed ID: 17064068
    [Abstract] [Full Text] [Related]

  • 20. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V.
    Biopolymers; 2008 May 02; 89(5):372-9. PubMed ID: 17937404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.